Chroma Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   2 Diseases  3 Products   2 Trials   164 News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nanatinostat (VRx-3996) / Viracta Therap
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”)

Not yet recruiting
2
150
Europe
Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04]
 
 
NAVAL-1, NCT05011058 / 2020-005197-10: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Terminated
2
102
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
12/24
01/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT06302140: A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Recruiting
1
14
Europe
[14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets
Viracta Therapeutics, Inc.
Advanced Cancer
02/25
10/25
VT3996-301, NCT05166577: Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Terminated
1
26
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
10/24
01/25
tefinostat (CHR-2845) / Chroma Therap
2015-002281-23: A clinical trial to test the safety and effectiveness of a new drug, tefinostat, for patients with chronic myelomonocytic leukaemia

Ongoing
2
40
Europe
Tefinostat, CHR-2845, Capsule
Cardiff University
Chronic myelomonocytic leukaemia (CMML), CMML is a form of leukaemia characterised by high numbers of white blood cells called monocytes in the blood and bone marrow., Diseases [C] - Cancer [C04]
 
 
CSF1R antagonist / Chroma Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nanatinostat (VRx-3996) / Viracta Therap
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”)

Not yet recruiting
2
150
Europe
Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04]
 
 
NAVAL-1, NCT05011058 / 2020-005197-10: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Terminated
2
102
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc., Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
12/24
01/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
NCT06302140: A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Recruiting
1
14
Europe
[14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets
Viracta Therapeutics, Inc.
Advanced Cancer
02/25
10/25
VT3996-301, NCT05166577: Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Terminated
1
26
Canada, US, RoW
Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda
Viracta Therapeutics, Inc.
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
10/24
01/25
tefinostat (CHR-2845) / Chroma Therap
2015-002281-23: A clinical trial to test the safety and effectiveness of a new drug, tefinostat, for patients with chronic myelomonocytic leukaemia

Ongoing
2
40
Europe
Tefinostat, CHR-2845, Capsule
Cardiff University
Chronic myelomonocytic leukaemia (CMML), CMML is a form of leukaemia characterised by high numbers of white blood cells called monocytes in the blood and bone marrow., Diseases [C] - Cancer [C04]
 
 
CSF1R antagonist / Chroma Therap
No trials found

Download Options